Histamine H₃ receptors, the complex interaction with dopamine and its implications for addiction.
paper
Cited
Public
Unavailable
- Authors
- Ellenbroek, B A
- Year
- 2013
- Journal
- British journal of pharmacology
- PMID
- 23647606
- DOI
- 10.1111/bph.12221
- PMCID
- PMC3764848
Histamine H₃ receptors are best known as presynaptic receptors inhibiting the release of histamine, as well as other neurotransmitters including acetylcholine and dopamine. However, in the dorsal and ventral striatum, the vast majority of H₃ receptors are actually located postsynaptically on medium sized spiny output neurons. These cells also contain large numbers of dopamine (D₁ and D₂) receptors and it has been shown that H₃ receptors form heterodimers with both D₁ and D₂ receptors. Thus, the anatomical localization of H₃ receptors suggests a complex interaction that could both enhance and inhibit dopaminergic neurotransmission. Dopamine, especially within the striatal complex, plays a crucial role in the development of addiction, both in the initial reinforcing effects of drugs of abuse, as well as in maintenance, relapse and reinstatement of drug taking behaviour. It is, therefore, conceivable that H₃ receptors can moderate the development and maintenance of drug addiction. In the present review, we appraise the current literature on the involvement of H₃ receptors in drug addiction and try to explain these data within a theoretical framework, as well as provide suggestions for further research.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | 2019 | 31740666 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Development and Preclinical Characterization of [<sup>18</sup>F]H3-2406 and [<sup>18</sup>F]H3-2407 for Positron Emission Tomography Imaging of the Histamine Subtype-3 Receptor. | Song Z et al. | — | 2025 | → |
| Histamine Modulation of the Basal Ganglia Circuitry in the Motor Symptoms of Parkinson's Disease. | Zhu HX et al. | — | 2025 | → |
| Molecular Insights into Bromocriptine Binding to GPCRs Within Histamine-Linked Signaling Networks: Network Pharmacology, Pharmacophore Modeling, and Molecular Dynamics Simulation. | Dermawan D et al. | — | 2025 | → |
| Predicted functional alterations in colonic microbiota metabolism underlie ethanol consumption and preference behavior in mice. | Velten Mendes M et al. | — | 2025 | → |
| Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for Psychosis. | Knight SR et al. | — | 2025 | → |
| Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders. | Szukiewicz D | — | 2024 | → |
| Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease. | Buzoianu AD et al. | — | 2023 | → |
| Neuroprotective effect of histamine H3 receptor blockade on methamphetamine-induced cognitive impairment in mice. | Luo H et al. | — | 2023 | → |
| The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia. | Arumuham A et al. | — | 2023 | → |
| Identification of Functional CircRNA-miRNA-mRNA Regulatory Network in Dorsolateral Prefrontal Cortex Neurons of Patients With Cocaine Use Disorder. | Chen Y et al. | — | 2022 | → |
| The Histamine H<sub>4</sub> Receptor Participates in the Neuropathic Pain-Relieving Activity of the Histamine H<sub>3</sub> Receptor Antagonist GSK189254. | Borgonetti V et al. | — | 2022 | → |
| Histamine H<sub>3</sub> receptor and cholinesterases as synergistic targets for cognitive decline: Strategies to the rational design of multitarget ligands. | Lopes FB et al. | — | 2021 | → |
| Intrauterine hyperglycemia impairs memory across two generations. | Zou K et al. | — | 2021 | → |
| Regulation of membrane NMDA receptors by dynamics and protein interactions. | Petit-Pedrol M et al. | — | 2021 | → |
| Fundamental features of receptor-mediated Gα<sub>i/o</sub> activation in human prefrontal cortical membranes: A postmortem study. | Odagaki Y et al. | — | 2020 | → |
| Histamine H<sub>3</sub> receptor gene variants associated with drug abuse in patients with cocaine use disorder. | Pallardo-Fernández I et al. | — | 2020 | → |
| Region-specific regulation of central histaminergic H3 receptor expression in a mouse model of cow's milk allergy. | Germundson DL et al. | — | 2020 | → |
| Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. | Thorpy MJ et al. | — | 2020 | → |
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | Cheng Z et al. | — | 2019 | → |
| Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats. | Belin-Rauscent A et al. | — | 2018 | → |
| Functional histamine H<sub>3</sub> and adenosine A<sub>2A</sub> receptor heteromers in recombinant cells and rat striatum. | Márquez-Gómez R et al. | — | 2018 | → |
| Merging the Pathophysiology and Pharmacotherapy of Tics. | Augustine F et al. | — | 2018 | → |
| Molecular Imaging in Huntington's Disease. | Wilson H et al. | — | 2018 | → |
| Oral Pharmacotherapy for Benign Essential Blepharospasm. | Hirabayashi KE et al. | — | 2018 | → |
| Functional histamine H<sub>3</sub>and adenosine A<sub>2A</sub>receptor heteromers in recombinant cells and rat striatum | Márquez-Gómez R et al. | — | 2017 | — |
| Recent Progress in Understanding the Conformational Mechanism of Heterotrimeric G Protein Activation. | Duc NM et al. | — | 2017 | → |
| The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry. | Rapanelli M | — | 2017 | → |
| The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. | Sfera A et al. | — | 2017 | → |
| Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. | Jiménez-Jiménez FJ et al. | — | 2017 | → |
| Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors. | Yadav M et al. | — | 2016 | → |
| High-throughput screening and radioligand binding studies reveal monoamine oxidase-B as the primary binding target for d-deprenyl. | Lesniak A et al. | — | 2016 | → |
| Structural and functional analogies and differences between histidine decarboxylase and aromatic l-amino acid decarboxylase molecular networks: Biomedical implications. | Sanchez-Jiménez F et al. | — | 2016 | → |
| The Histamine H3 Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons. | Rapanelli M et al. | — | 2016 | → |
| Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs. | Vanhanen J et al. | — | 2015 | → |
| Aminooxy analog of histamine is an efficient inhibitor of mammalian L-histidine decarboxylase: combined in silico and experimental evidence. | Castro-Oropeza R et al. | — | 2014 | → |
| Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects. | Moreno E et al. | — | 2014 | → |
| Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). | Nguyen M et al. | — | 2014 | → |
| New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present). | Łażewska D et al. | — | 2014 | → |
| The other side of the histamine H3 receptor. | Ellenbroek BA et al. | — | 2014 | → |
| Histamine pharmacology: four years on. | Chazot PL | — | 2013 | → |
| The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. | Mereu M et al. | — | 2013 | → |